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A B S T R A C T
The aim of this study was to calculate the relative prevalence of all phenotypes of polycystic ovary syndrome (PCOS)
and to compare them for anthropometrical, hormonal and metabolic differences according to the Rotterdam Criteria. A
total of 300 women with PCOS aged 26.7±5.6 years (mean±SD) and 100 women aged 28.3±4.1 years (mean±SD) were
included in a control group. Anthropometrical, hormonal and metabolic parameters were compared between the groups.
The most prevalent phenotype in our population was the most severe, phenotype A (56.7%), followed by phenotype D
(26.7%) and phenotype C (14.3%). Phenotype B was present in only 2.3% of patients. The four main phenotypes did not
differ in age, BMI and WHR. Women with phenotypes A and C had increased levels of LH and an increased LH/FSH ra-
tio along with elevated androgen levels compared to the other groups. Serum glucose levels did not differ between the
groups studied, however, higher levels of insulin, GIR and HOMA-IR were found between phenotype A and the control
group. Phenotype C PCOS or ovulatory PCOS have the same characteristics as classic PCOS, however in a more mild
form, which represents a transition between the classic form and the control group. Compared to the control group, phe-
notype D had higher mean levels of serum testosterone (still within normal range) along with elevated LH levels and
LH/FSH ratio, similar to classic PCOS. However, compared with women diagnosed with PCOS based on hyperandro-
genism, oligo-ovulation and polycystic ovaries, these patients demonstrated milder endocrine and metabolic abnormali-
ties. Therefore, from an endocrine point of view, our study supports the inclusion of a normoandrogenic anovulatory phe-
notype in PCOS diagnostic criteria.
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Introduction
Polycystic ovary syndrome (PCOS) is a complex endo-
crine and metabolic disorder with an unclear etiology
and an underlying pathogenic mechanism.
The endocrine abnormalities in PCOS include hyper-
androgenism of ovarian and/or adrenal origin, which var-
ies in clinical presentation, leading to arrested follicular
development and consequently anovulation and polycys-
tic ovarian morphology. The majority of women with
PCOS have increased luteinizing hormone (LH) secre-
tion further worsening the hyperandrogenemia. Meta-
bolic characteristics of PCOS include central adiposity
and hyperinsulinemia with consequential insulin resis-
tance further exacerbating hyperandrogenism. Endocri-
ne and metabolic abnormalities seen in PCOS range in
clinical manifestation and may vary among affected wo-
men, thus creating a heterogeneous biochemical and
clinical phenotype and ultimately producing difficulties
in establishing a detailed diagnosis of the syndrome.
With an uncertain etiology, causal mechanisms and
varying symptom presentation, PCOS is defined by con-
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sensual criteria. For many years only the classic pheno-
type, characterized by anovulation and hyperandroge-
nism/hyperandrogenemia was included in the diagnosis
of PCOS1. The ESHRE/ASRM or Rotterdam Criteria
broadened the phenotypic spectrum by including two ad-
ditional phenotypes2. The four central phenotypes de-
fined by these guidelines include: A) hyperandrogenism,
chronic anovulation and polycystic ovaries (classic PCOS);
B) hyperandrogenism and chronic anovulation with nor-
mal ovaries (classic PCOS); C) hyperandrogenism and
polycystic ovaries with ovulatory cycles (ovulatory hy-
perandrogenic PCOS); and D) chronic anovulation and
polycystic ovaries without clinical or biochemical hyper-
androgenism (anovulatory normoandrogenic PCOS). Ex-
pansion of diagnostic criteria doubled the number of
women diagnosed by PCOS. Since PCOS is a genetic dis-
order with a likelihood of developing serious reproduc-
tive and metabolic consequences, such women may have
life-long implications, affecting her health, health insur-
ance, and possibly that of her relatives and offspring. In
addition, PCOS may result in a significant economic bur-
den to the health care system, consequently having im-
plications on health insurance in such patients. There-
fore, it is imperative to accentuate the importance of a
correct identification of specific phenotypes in women di-
agnosed with PCOS3.
Currently there is a limited amount of data on the
clinical characteristics and the endocrine-metabolic fea-
tures in women belonging to the novel PCOS phenotypes
as defined by the Rotterdam Criteria. Moreover, with sig-
nificant variations in PCOS presentation seen in differ-
ent ethnic populations, additional studies are needed.
However, it is important to note that an attempt to gen-
eralize data obtained from any single ethnic group to
other population groups should be approached with cau-
tion. As a result, the aim of this study was to report the
relative prevalence of all four Rotterdam PCOS pheno-
types in a medical setting and compare all phenotypes for
anthropometrical, hormonal, and metabolic differences.
Although a true prevalence study would survey a com-
munity, our clinic represents a reference center for wo-
men with all types of menstrual irregularities and clini-
cal signs of androgen excess, thus we could assume that




Between April 2010 and October 2012, 300 women
with PCOS aged 26.7±5.6 years (mean±SD) and 100
women in a control group, aged 28.3±4.1 years (mean±
SD) were enrolled in the study. They were included in the
study during their treatment at the Human Reproduc-
tion Unit of the Department of Obstetrics and Gynecol-
ogy, at the University Medical Centre in Zagreb.
The diagnosis of PCOS was based on the Rotterdam
Consensus Criteria2. Clinical hyperandrogenism was de-
fined by the presence of hirsutism (assessed by Ferri-
man-Gallwey-Lorenzo score, with patients having scores
³8 considered as hirsute)4. Biochemical hyperandroge-
nemia was defined by a serum level of total testosterone
(TT) more than 2.0 nmol/L, a free testosterone (FT) level
greater than 26 pmol/L, an androstendione (A) level
greater than 12 nmol/L or dehydroepiandrosterone sul-
phate (DHEAS) greater than 10 µmol/L. Menstrual ir-
regularities were defined by the presence of amenorrhea/
oligomenorrhea or anovulation determined by progester-
one less than 9.54 nmol/L levels on day 21 of two consec-
utive menstrual cycle. The diagnosis of polycystic ovaries
(PCO) by ultrasonography was based on the established
criteria5. In order to avoid inter-observer variations, the
same examiner performed the ultrasound. Other endo-
crinopathies and related disorders were excluded by mea-
suring basal serum 17-hydroxyprogesterone (17-OHP),
prolactin (PRL), thyroid stimulating hormone (TSH),
and cortisol levels. The control group consisted of 100
healthy volunteers preparing for in vitro fertilization cy-
cles due to male factor infertility. They had no menstrual
cycle abnormalities, nor clinical or biochemical evidence
of hyperandrogenism or PCO findings on ultrasound.
The patients registered in our study had not taken
any medications that could affect these values for at least
six months prior to enrollment. They were enrolled at
the early follicular phase of the spontaneous or proges-
terone induced menstrual cycle (day 3–5) when blood
samples for hormonal and biochemical analysis were
drawn, transvaginal ultrasound (TV – US) was perfor-
med and body mass index (BMI, calculated as a weight
(kg) / height (m2) and waist to hip ratio (WHR) were cal-
culated. At enrollment, informed consent was obtained
from all participants. The University of Zagreb Medical
School Ethics Committee approved the study, protocol
No. 04–1116–2006.
Biochemical analysis
Serum luteinizing hormone (LH), follicle–stimulating
hormone (FSH), and total testosterone (TT) concentra-
tions were determined by chemiluminescent immunome-
tric assays using LH – Vitros, FSH – Vitors and Testos-
terone – Vitros (Ortho Clinical Diagnostics, Johnson &
Johnson, Rochester, NY, USA). Serum sex hormone bind-
ing globulin (SHBG), dehydroepiandrosterone sulphate
(DHEAS) and androstendione (A) were measured using
chemiluminescent immunometric assays using SHBG –
Immulite, DHS – Immulite and Androstendion – Im-
mulite (Siemens Healthcare Diagnostic Inc, Deerfield, Il
USA). The intra – assay and inter – assay coefficient of
variation were between 1.5 and 7.9%. The plasma glu-
cose level (Glc) was determined by the UV – photometric
hexokinase method and the serum insulin (Ins) level by
chemiluminescent immunometric assay using Insulin –
Immulite (Siemens Healthcare Diagnostics Inc, Deer-
field, IL, USA). Insulin resistance (IR) was quantified by
calculating homeostatic model assessment of IR (HOMA
IR) (fasting Ins mIU/L x fasting Glc mmol/L/22.5)6 and
by calculating fasting glucose to insulin ratio (GIR). In-
sulin resistance was defined by a HOMA-IR of 2.5 or










higher based on original HOMA research6. Free testos-
terone (FT) was calculated from TT and SHBG as previ-
ously described7 using a web-based calculator (http://
www.issam.ch/freetesto.htm).
Women with PCOS were divided into four groups,
based on phenotype, according to their clinical character-
istics: oligo/anovulation (OA), clinical and/or biochemical
hyperandrogenism (HA) and polycystic ovaries on ultra-
sound (PCO). Phenotype A: OA+HA+PCO; phenotype
B: OA+HA; phenotype C: HA+PCO (ovulatory hyper-
androgenic); and phenotype D: OA+PCO (anovulatory
normoandrogenic).
Statistical analysis
Frequency of different phenotypes is described by
percentages. The hormonal and clinical data are pre-
sented as mean±standard deviation. Comparisons of
continuous variables across the four groups were per-
formed using analysis of variance (ANOVA). Tukey HSD
post hoc test was used to determine significant differ-
ences between the groups. All statistical analyses were
completed using the SPSS for Windows (version 15.0,
SPSS Inc., Chicago, IL, USA). A p value <0.05 was con-
sidered statistically significant.
Results
The most prevalent phenotype in our population was
the most severe, phenotype A (56.7%), followed by phe-
notype D (26.7%) and phenotype C (14.3%) as presented
in Table 1. Phenotype B was present in only 7/300 PCOS
patients (2.3%) and was therefore excluded from further
analysis (Table 1).
The clinical and hormonal parameters in the different
PCOS and control groups of patients are presented in Ta-
ble 2. Mean age, BMI and WHR was similar in all pheno-
types of PCOS, and did not differ compared to the control
group (Table 2.). As expected, patients in all three PCOS
groups had significantly higher levels of LH, serum TT,
FT, GIR and HOMA-IR, whereas serum SHBG and FSH
were significantly lower compared to control group (Ta-
ble 2). There were no statistical differences in BMI be-
tween the three study groups. Patients with PCOS, phe-
notype A, presented with a statistically significant higher
LH level and LH/FSH ratio compared to the other two
phenotypes and the control group (p<0.001, Table 2).
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TABLE 1
CLINICAL PRESENTATION AND FREQUENCY OF THE
DIFFERENT PCOS PHENOTYPES
Phenotype
Characteristic A (N=170) B (N=7) C (N=43) D (N=80)
OA + + – +
HA + + + –
PCO + – + +
Frequency (%) 56.7 2.3 14.3 26.7
Abbreviations: OA – oligo/anovulation; HA – Clinical and/or
biochemical hyperandrogenism; PCO – polycystic ovaries
TABLE 2
CLINICAL AND HORMONAL CHARACTERISTICS OF DIFFERENT PCOS PHENOTYPES AND CONTROL GROUP
Phenotype A Phenotype C Phenotype D Control p-values*
Age (years) 27.7±5.8 27.5±5.6 26.9±5.4 28.3±4.1 ns
BMI (kg/m2) 24.5±5.3 24.3±4.2 25.5±4.7 23.3±4.1 ns
WHR 0.79±0.08 0.77±0.07 0.82±0.1 0.79±0.07 ns
FSH (IU/L) 3.9±1.2d 4.8±1.4d 3.7±1.0d 5.5±1.6 a,b,c <0.001
LH (IU/L) 10.0±4.3b,c,d 8.1±1.9a,d 7.3±0.9a,d 3.7±0.9 a,b,c <0.001
LH/FSH 2.8±1.6b,c,d 2.0±1.1a,d 2.3±0.9a,d 0.7±0.8 a,b,c <0.001
TT (nmol/L) 2.7 ±0.6B,c,d 2.3±0.7A,c,d 1.4±0.3a,b 1.3±0.5 a,b <0.001
FT (pmol/L) 53.1±21.7c,d 44.8±26.8c,d 25.3±12.9a,b,d 14.2±6.6 a,b,c <0.001
A (nmol/L) 11.6±4.7d 12.2± 5.9d 10.0±6.3d 7.6±2.5 a,b,c <0.001
DHEAS (ìmol/L) 7.6±3.1d 7.1±2.9 d 6.7±3.2 5.0±1.9 a,b <0.001
SHBG (nmol/L) 35.3±16.7c,d 37.6±19.5c,d 62.3±20.4a,b,d 71.2±22.2 a,b,c <0.001
Fasting glucose (mmol/L) 4.5±0.5 4.4±0.4 4.4±0.4 4.4±0.5 Ns
Fasting insulin (mIU/L) 14.4±7.9d 12.0±9.8 9.6±5.5 6.5±2.6 a <0.001
HOMA-IR 2.9±1.4d 2.4±2.0 1.9±1.1 1.3±0.6 a <0.001
GIR 10.7±4.1d 9.0±4.6 12.5±6.0 14.8±7.2 a <0.001
Abbreviations: BMI – body mass index, WHR – waist to hip ratio, FSH – follicle stimulating hormone, LH – luteinizing hormone, TT –
total testosterone, FT – free testosterone, DHEAS – dehydroepiandrosterone sulphate, SHBG – sex hormone binding globulin, HOMA
– IR – homeostatic model assessment of insulin resistance, GIR – glucose to insulin ratio
* ANOVA test; ap<0.001 compared with phenotype A, bp<0.001 compared with phenotype C, cp<0.001 compared with phenotype D;









Both new Rotterdam phenotype C and D have statisti-
cally significant higher levels of LH than the control
group (p<0.001, Table 2). The phenotype A group also
presented with significantly higher levels of total testos-
terone levels compared to the other two phenotypes and
controls (p<0.01 and p<0.001, respectively, Table 2). Se-
rum levels of other androgens (androstendione and
DHEAS), as well as serum SHBG levels, were found to be
similar between the different PCOS phenotypes (Table
2). Serum levels of glucose were not found to be different
between groups studied but higher levels of insulin, GIR
and HOMA-IR were found between phenotype A and the
control group (p<0.001, Table 2).
Discussion and Conclusion
The Rotterdam Criteria2 added two phenotypes of
women with PCOS: women with normal menstrual peri-
ods and normal fertility, but who have androgen excess
and polycystic ovaries on ultrasound (phenotype C), and
women with oligomenorrhea and polycystic ovaries on
ultrasound, but normal androgen excess (phenotype D).
The names given to these phenotypes in this study are
arbitrary and not accepted by all experts. In the recently
published Consensus on Women’s Health, it is noted that
geographic location, ethnic origin and even cultural and
social practices are contributing factors to the different
phenotypes of PCOS8. Therefore, in our study, informa-
tion on relative prevalence of the main phenotypes of
PCOS in the Croatian population was given.
The most common phenotype in our study was pheno-
type A (56.7%), characterized by oligo/anovulation, clini-
cal and/or biochemical hyperandrogenism and a poly-
cystic appearance of the ovaries. All published studies
reported this phenotype to be the most prevalent9–14.
This phenotype is included in all three-consensus cri-
teria1,2,15 and certainly represents the basis of PCOS di-
agnosis. The prevalence of the other three groups differs
between published studies9–14.
In our population, the less frequent phenotype is phe-
notype B (2.3%), characterized by oligo/anovulation, clin-
ical and/or biochemical hyperandrogenism with normal
appearing ovaries on the ultrasound exam. Although this
finding is in accordance with the studies for other popu-
lation groups9–14, other authors reported a higher fre-
quency of phenotype B (22.8–7.6%) compared to those
found in our study. This difference can be explained by
the fact that American gynecologists traditionally do not
perform ultrasound, while European gynecologists pre-
fer to view polycystic ovaries on ultrasound as a means of
diagnosing PCOS. The other reason for differences in
frequency of diagnosing this phenotype is that endocri-
nologists, who do not use ultrasound, diagnose many
cases of PCOS. In our study, an experienced gynecologist
performed a complete ultrasound exam.
Phenotype C, characterized by hyperandrogenism
and a polycystic appearance of the ovaries was repre-
sented by 14.3% in our study groups. This is in accor-
dance with studies from Bulgaria10, and Poland13. We ex-
pected to have similar results to the Italian population14
who reported the prevalence of this phenotype in 28.8%
of the PCOS population, attributing to the fact that
women from Mediterranean ancestry tend to have more
body hair than women of other ethnicities. Phenotype D
is the second most frequent phenotype in our study
group, represented by 26.7%. Other studies reported the
prevalence of this unusual and most controversial pheno-
type as having a 19.9–8.4% incidence9–14. Again, the reason
for these differences could lie in the variances of examin-
ing PCOS patients between American and European gy-
necologists and endocrinologists. Endocrinologists treat
many PCOS patients without doing ultrasounds in the
office. Additionally, many gynecologists in the US send
patients to radiology, where reports are usually less in-
formative. Furthermore, normal androgen levels and ab-
normal menstrual cycles characterize this phenotype;
therefore it is more logical to be referred to a gynecolo-
gist rather than an endocrinologist. The elevated level of
LH, distinguishing this group of patients from the con-
trol groups, is currently not considered to be a diagnostic
feature of PCOS2. Nevertheless, evidence attributing to
the unusual PCOS phenotype D is scarce, and therefore,
new and additional studies are needed. As a result, the
Androgen Excess and PCOS Society have suggested ex-
cluding patients with normal androgen levels among the
PCOS phenotypes until more data becomes available15.
In our study, we provided the difference in anthropo-
metrical, hormonal, and metabolic characteristics be-
tween the main PCOS phenotypes, according to the Rot-
terdam Criteria and the control groups. The four main
phenotypes studied did not differ in age, BMI and WHR.
The majority of studies demonstrated elevated BMI,
WHR, glucose, IR, GIR and HOMA-IR in the classic
PCOS phenotypes (A and B) compared to Rotterdam
phenotype (C and D)16–18. Previously, we reported that
there is a low prevalence of obesity in the Croatian popu-
lation with PCOS, for this reason, the difference between
our study and other studies can be explained by such a
finding19. As there is evidence of an increasing rate of
obesity20–23, especially in childhood24, we can expect more
pronounced metabolic differences between the pheno-
types in years to come.
Type A or classic PCOS represents the most common
form of PCOS, characterized by increased levels of LH
and an increased LH/FSH ratio, with increased androgen
levels. Although serum levels of insulin and HOMA-IR
were not found to be different between the groups stud-
ied, higher levels of these parameters were found be-
tween phenotype A and the control group representing
the elevated risk for diabetes type 2, a feature of PCOS.
Type C PCOS or ovulatory PCOS have the same char-
acteristics as classic PCOS but in a milder form and rep-
resents the transition between the classic form and the
controls. Despite the proven ovulatory cycles, patients
have elevated levels of LH and an increased LH/FSH ra-
tio compared to control group.
Type D or normoandrogenic anovulatory PCOS rep-
resents the conflicting group. Compared to the control










group, these women have higher mean levels of serum
testosterone (still within normal range) and elevated LH
levels and an increased LH/FSH ratio similar to classic
PCOS. However, compared with women diagnosed with
PCOS based on hyperandrogenism, oligo-ovulation and
polycystic ovaries, these patients demonstrated milder
endocrine and metabolic abnormalities. Therefore, from
an endocrine point of view, our study supports the inclu-
sion of a normoandrogenic anovulatory phenotype in
PCOS diagnostic criteria. In the long run, it will be inter-
esting to note, if these women will progress to a more se-
vere phenotype, and how pronounced their cardiac risk
factors will progress with age. The majority of studies re-
ported less adverse metabolic profiles for the newly in-
troduced Rotterdam phenotypes11,24,25. However, in these
studies, due to a lack of weight matching, it is not possi-
ble to determine whether a worsened metabolic profile is
due to differences in adiposity or other factors. In our
study, all groups have similar BMI and WHR profiles.
In conclusion, four phenotypes of PCOS share the ab-
normalities in LH, LH/FSH ratio and androgen parame-
ters, but vary in severity. With an abnormal secretion of
gonadotropins, characteristic of PCOS, new phenotypes
merit inclusion in the PCOS spectrum. Only the most se-
vere phenotype showed abnormalities in insulin resis-
tance in comparison to women in the control group.
Whether these newly introduced phenotypes have the in-
trinsic predisposition to an adverse metabolic profile in-
dependent of obesity, other molecular genetic studies will
be demonstrative. Certainty with regards to PCOS diag-
nostic criteria and the inclusion of various phenotypes
and their endocrine-metabolic risks will be not be ex-
plained until research shows the underlying cause. An
accurate definition of PCOS will be reached when genetic
analyses of the population are completed to determine
the genetic–pathophysiologic phenotypes.
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OSOBINE RAZLI^ITIH FENOTIPOVA POLICISTI^NIH JAJNIKA U HRVATSKOJ
DIJAGNOSTICIRANIH PO ROTTEDRAMSKIM KRITERIJIMA
S A @ E T A K
Cilj ovog istra`ivanja bio je izra~unati relativnu zastupljenost svih fenotipova sindroma policisti~nih jajnika (PCOS),
dijagnosticiranih po Rotterdamskom kriteriju i usporediti njihove antropometrijske, hormonske i metaboli~ke razlike.
Analizirano je ukupno 300 `ena s PCOS-om u dobi od 26,7±5,6 godina (srednja vrijednost ± SD) i 100 `ena iz kontrolne
skupine u dobi od 28,3±4,1 godina (srednja vrijednost ± SD). Antropometrijski, hormonalni i metaboli~ki parametri
uspore|eni su izme|u navedenih skupina. Naju~estaliji fenotip u na{oj populaciji je onaj najte`i – fenotip A (56,7%),
slijede ga fenotip D (26,7%) i fenotip C (14,3%). Fenotip B je bio prisutan samo u 2,3% ispitanica. ^etiri glavna feno-
tipova nisu se razlikovala u dobi, BMI i WHR. U fenotipovima A i C na|ene su povi{ene razine LH te omjer izme|u LH i
FSH kao i povi{ene vrijednosti androgena u odnosu na ostale skupine. Serumske razine glukoze nisu se zna~ajno razli-
kovale izme|u ispitivanih skupina, ali su prona|ene vi{e serumske razine inzulina, GIR i HOMA-IR izme|u fenotipa A
i kontrolne skupine. Fenotip C PCOS imao je iste karakteristike kao klasi~ni PCOS, ali u bla`em obliku i predstavlja
prijelaz izme|u klasi~ne forme i kontrole. U usporedbi s kontrolnom skupinom, fenotip D ima vi{u razinu serumskog
testosterona (iako u granicama normalnih vrijednosti) te povi{en LH i LH / FSH omjer sli~no kao u klasi~nom PCOS.
Me|utim, u usporedbi sa `enama s PCOS dijagnosticiranim na temelju hiperandrogenizma, oligoovulacije i policis-
ti~nih jajnika, ove ispitanice pokazuju blaze endokrinolo{ke i metaboli~ke abnormalnosti. Stoga s endokrinolo{kog gle-
di{ta na{a studija podupire uklju~ivanje normoandrogenog anovulatornog fenotipa PCOS-a u dijagnosti~ke kriterije.
D. Pavi~i} Baldani et al.: Phenotypes in PCOS, Coll. Antropol. 37 (2013) 2: 477–482
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